File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Mechanisms of the coronary vascular effects of platelet-activating factor in the rat perfused heart

TitleMechanisms of the coronary vascular effects of platelet-activating factor in the rat perfused heart
Authors
Issue Date1991
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0007-1188&site=1
Citation
British Journal Of Pharmacology, 1991, v. 103 n. 1, p. 1097-1102 How to Cite?
Abstract1. In a revious study it was demonstrated that bolus injections of platelet-activating factor (PAF) in the rat perfused heart resulted in coronary vasodilatation, vasoconstriction or the combination of both, depending on the amount of PAF that was injected. In the present study, the mechanisms of these coronary vascular effects of PAF in the rat perfused heart were investigated. 2. Pretreatment of the rat perfused heart with the PAF antagonists FR-900452 or BN-52021 did not affect the vasodilator effect of PAF but eliminated the vasoconstrictor effect of PAF. FR-900452 had no effect on the vasoconstrictor response to leukotriene C4 (LTC4) or LTD4. 3. The cyclo-oxygenase inhibitor, indomethacin, did not modify the coronary vascular effects of PAF. However L-649,923 (a leukotriene antagonist) and MK-886 (a leukotriene synthesis inhibitor) eliminated both the vasodilator and vasoconstrictor effects of PAF. 4. When leukotrienes were administered by bolus injection in the rat perfused heart, LTB4 produced vasodilatation while LTC4 and LTD4 produced vasoconstriction. L-649,923 blocked both the vasodilator and vasoconstrictor effects of the leukotrienes tested. 5. The results suggest that lipoxygenase products are responsible for both the vasodilator and vasoconstrictor actions of PAF in the coronary vasculature of the rat perfused heart while the cyclo-oxygenase products do not play a significant role. The ineffectiveness of PAF antagonists in blocking the vasodilatation produced by PAF is compatible with the concept that there may be multiple PAF receptors.
Persistent Identifierhttp://hdl.handle.net/10722/171003
ISSN
2015 Impact Factor: 5.259
2015 SCImago Journal Rankings: 2.368
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHu, Wen_US
dc.contributor.authorKinnaird, AAAen_US
dc.contributor.authorMan, RYKen_US
dc.date.accessioned2012-10-30T06:11:47Z-
dc.date.available2012-10-30T06:11:47Z-
dc.date.issued1991en_US
dc.identifier.citationBritish Journal Of Pharmacology, 1991, v. 103 n. 1, p. 1097-1102en_US
dc.identifier.issn0007-1188en_US
dc.identifier.urihttp://hdl.handle.net/10722/171003-
dc.description.abstract1. In a revious study it was demonstrated that bolus injections of platelet-activating factor (PAF) in the rat perfused heart resulted in coronary vasodilatation, vasoconstriction or the combination of both, depending on the amount of PAF that was injected. In the present study, the mechanisms of these coronary vascular effects of PAF in the rat perfused heart were investigated. 2. Pretreatment of the rat perfused heart with the PAF antagonists FR-900452 or BN-52021 did not affect the vasodilator effect of PAF but eliminated the vasoconstrictor effect of PAF. FR-900452 had no effect on the vasoconstrictor response to leukotriene C4 (LTC4) or LTD4. 3. The cyclo-oxygenase inhibitor, indomethacin, did not modify the coronary vascular effects of PAF. However L-649,923 (a leukotriene antagonist) and MK-886 (a leukotriene synthesis inhibitor) eliminated both the vasodilator and vasoconstrictor effects of PAF. 4. When leukotrienes were administered by bolus injection in the rat perfused heart, LTB4 produced vasodilatation while LTC4 and LTD4 produced vasoconstriction. L-649,923 blocked both the vasodilator and vasoconstrictor effects of the leukotrienes tested. 5. The results suggest that lipoxygenase products are responsible for both the vasodilator and vasoconstrictor actions of PAF in the coronary vasculature of the rat perfused heart while the cyclo-oxygenase products do not play a significant role. The ineffectiveness of PAF antagonists in blocking the vasodilatation produced by PAF is compatible with the concept that there may be multiple PAF receptors.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0007-1188&site=1en_US
dc.relation.ispartofBritish Journal of Pharmacologyen_US
dc.subject.meshAnimalsen_US
dc.subject.meshBlood Pressure - Drug Effectsen_US
dc.subject.meshCoronary Circulation - Drug Effectsen_US
dc.subject.meshDiterpenesen_US
dc.subject.meshGinkgolidesen_US
dc.subject.meshHeart - Drug Effectsen_US
dc.subject.meshIndoles - Pharmacologyen_US
dc.subject.meshIndomethacin - Pharmacologyen_US
dc.subject.meshLactones - Pharmacologyen_US
dc.subject.meshLeukotriene Antagonistsen_US
dc.subject.meshLeukotriene B4 - Pharmacologyen_US
dc.subject.meshPerfusionen_US
dc.subject.meshPhenylbutyrates - Pharmacologyen_US
dc.subject.meshPiperazinesen_US
dc.subject.meshPlatelet Activating Factor - Antagonists & Inhibitors - Pharmacologyen_US
dc.subject.meshRatsen_US
dc.subject.meshRats, Inbred Strainsen_US
dc.subject.meshSrs-A - Antagonists & Inhibitors - Pharmacologyen_US
dc.titleMechanisms of the coronary vascular effects of platelet-activating factor in the rat perfused hearten_US
dc.typeArticleen_US
dc.identifier.emailMan, RYK:rykman@hkucc.hku.hken_US
dc.identifier.authorityMan, RYK=rp00236en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1476-5381.1991.tb12306.x-
dc.identifier.pmid1652337-
dc.identifier.scopuseid_2-s2.0-0025763181en_US
dc.identifier.volume103en_US
dc.identifier.issue1en_US
dc.identifier.spage1097en_US
dc.identifier.epage1102en_US
dc.identifier.isiWOS:A1991FJ55000015-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridHu, W=7404360099en_US
dc.identifier.scopusauthoridKinnaird, AAA=6603472891en_US
dc.identifier.scopusauthoridMan, RYK=7004986435en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats